Apria Completes Secondary Offering of Common Stock
Apria, Inc. (Nasdaq: APR) announced the completion of a secondary offering of 4,500,000 shares at $31.50 per share, generating gross proceeds of $141.75 million. The selling stockholder, affiliated with Blackstone, has granted underwriters a 30-day option to purchase an additional 675,000 shares. Apria did not issue any shares and did not receive net proceeds from this offering. The underwriting was led by Citigroup and Goldman Sachs, with several other firms participating. This offering was made through a prospectus filed with the SEC.
- The offering raised $141.75 million, potentially increasing market visibility.
- The underwriters' option for additional shares may indicate strong demand.
- Apria did not receive any proceeds from the sale, raising concerns about its capital needs.
- Shareholder dilution may occur if the underwriters exercise their option for additional shares.
INDIANAPOLIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today the completion of a secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of
Apria did not offer any shares of its common stock and did not receive any net proceeds from the sale of common stock by the selling stockholder. Citigroup and Goldman Sachs & Co. LLC acted as joint lead book-running managers for the offering. BofA Securities, UBS Investment Bank and Piper Sandler acted as joint book-running managers for the offering. Citizens Capital Markets, Fifth Third Securities, TD Securities, Academy Securities, Blaylock Van, LLC, Penserra Securities LLC and Stern acted as co-managers for the offering.
The offering of these securities was made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146 or by email at prospectus@citi.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, by facsimile at 1-212-902-9316 or by email at prospectus-ny@ny.email.gs.com; BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by emailing ol-prospectus-request@ubs.com; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by email at prospectus@psc.com or by telephone at 1-800-747-3924.
A registration statement, including a prospectus, relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and has become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Apria
Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy. Its approximately 280 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year. All of Apria’s locations are accredited by The Joint Commission.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include any statements regarding the proposed offering of Apria common stock and other non-historical statements. Forward-looking statements include all statements that do not relate solely to historical or current facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2021, each as filed with the SEC, as such factors may be updated from time to time in the Company’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the Company’s filings with the SEC. Investors are urged to consider carefully the disclosure in the Company’s filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Investor Contacts
Media Contacts
Mark.Corbae@westwicke.com
Kyle.Evans@westwicke.com
FAQ
What was Apria's secondary offering on November 15, 2021?
Who conducted the secondary offering for Apria?
Did Apria receive any proceeds from the secondary offering?
What are the implications of Apria's stock offering for shareholders?
